Changeflow GovPing Healthcare & Life Sciences LRRK2 Degrading Compounds for Parkinson's Disea...
Routine Notice Added Final

LRRK2 Degrading Compounds for Parkinson's Disease Treatment

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260085066A1) detailing bifunctional compounds designed to degrade LRRK2, a protein implicated in Parkinson's Disease. The application covers pharmaceutical compositions and methods for treating LRRK2-associated disorders.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a patent application (US20260085066A1) filed with the USPTO on September 6, 2023, concerning novel bifunctional compounds that induce the degradation of Leucine Rich Repeat Kinase 2 (LRRK2). The application outlines pharmaceutical compositions containing these compounds and their associated methods of use for treating disorders linked to LRRK2, specifically mentioning Parkinson's Disease.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signifies potential future developments in therapeutic treatments for Parkinson's Disease, which may impact research and development strategies for pharmaceutical and biotechnology companies operating in this therapeutic area. Companies involved in LRRK2 research or Parkinson's disease treatments should monitor the progress of this patent application and related intellectual property.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE

Application US20260085066A1 Kind: A1 Mar 26, 2026

Inventors

Steven M. Sparks, Handing Dong, Michael Berlin

Abstract

The present disclosure relates to bifunctional compounds that cause the degradation of LRRK2; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with LRRK2, including Parkinson's Disease.

CPC Classifications

C07D 413/14 A61K 31/506 A61K 31/5377 A61K 45/06 C07D 401/14 C07D 405/14 C07D 471/10

Filing Date

2023-09-06

Application No.

19109277

View original document →

Named provisions

LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 6th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085066A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Pharmaceutical Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Healthcare Medical Research

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!